Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: LGST) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC merger and operates in the biotechnology and life sciences sector. The company is developing allogeneic, off-the-shelf T-cell immunotherapy candidates targeting infectious diseases and oncology indications, positioning itself as an early-stage platform play in cellular medicine. Tevogen Bio filed its 10-K annual report with the U.S. Securities and Exchange Commission on April 29, 2024, reflecting its standing as a post-merger public company. For comprehensive filing data, SPAC transaction records, and pipeline tracking on Tevogen Bio Holdings and thousands of other companies, sign up for full data access on SpacDesk.